MCED Testing: Strategies for Mitigating the Risk of Overdiagnosis
Host: Brian P. McDonough, MD, FAAFP Guest: Nima Nabavizadeh, MD Guest: Tomasz Beer, MD, FACP While multi-cancer early detection (MCED) testing has the potential to significantly impact the way we approach cancer screening, it’s important to be aware of the risks associated with it, like overdiagnosis. That’s why Drs. Nima Nabavizadeh and Tom Beer join Dr. Brian McDonough to discuss the advantages and drawbacks of MCED testing and how we can mitigate the risk of overdiagnosis. Dr. Nabavizadeh is an Associate Professor in the Department of Radiation Medicine in the School of Medicine at OHSU in Portland, Oregon, and Dr. Beer is the Chief Medical Officer for Multi-Cancer Early Detection at Exact Sciences Corporation.